Market access is the set of strategies and evidence that secure a therapy’s price, reimbursement and availability, so that approved treatments actually reach the patients who need them.

HEOR generates the economic and outcomes evidence, and market access turns that evidence into pricing, reimbursement and payer agreement. The two work hand in hand.

It develops the value proposition, prepares HTA submissions, sets pricing strategy, engages payers, secures reimbursement and coverage, and plans launch and ongoing access.

Health technology assessment (HTA) is the process payers and agencies use to evaluate a therapy’s clinical and economic value before deciding whether to fund it.

A formulary is the list of medicines a payer or health system will cover, often with tiers that affect patient cost and access.

A value-based or outcomes-based agreement ties a therapy’s price or rebates to its real-world performance, sharing risk between the manufacturer and the payer.

Real-world evidence strengthens the value story, closes evidence gaps at and after launch, supports HTA submissions, and provides the endpoints that outcomes-based agreements run on.

It introduces Medicare price negotiation and inflation rebates, reshaping US pricing, launch sequencing and access strategy.

A centralized EU clinical assessment that feeds national HTA decisions, phasing in from 2025 to reduce duplicate evaluations across member states.

The organizations that fund healthcare and decide coverage, including national HTA bodies, government programs, commercial insurers, pharmacy benefit managers and health systems.

RWE Connect 2026 is a two-day real-world evidence summit in Boston bringing together the RWE, HEOR and market access leaders who generate and apply real-world evidence, with 40+ speakers and 150+ attendees.

14 to 15 October 2026 at the Hampton Inn by Hilton, Boston Seaport District, Boston, MA.